ACTRN12612000269831尚未招募未知
A 12-months parallel group randomised trial of patients with Chronic Obstructive Pulmonary Disease (COPD) comparing provision of a COPD action plan with dispensed antibiotics and oral steroids, against an action plan without dispensed medications, on action plan adherence and quality of life
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Physician Diagnosis of COPD
- •Post bronchodilator FEV1/FVC <0.7
- •Patient is enrolled in the respiratory chronic care program- a program based at Royal Prince Alfred Hospital Sydney Australia that provides regular planned home vists for patients with COPD, within Royal Prince Alfred hospitals catchment area.The program offers continuing health support through education and assistance to patients and their carers. This program augments existing respiratory services by enhancing communication and coordination of care between hospital, community services and general practitioners.
- •This care is provided by specialist nurses and physiotherapists.
排除标准
- •Treating clinician or respiratory chronic care team believes that the patient is unsuitable eg poor comprehension, inability to follow an action plan
- •Severe uncontroled other diseases that would likely interfere with study outcomes.
- •Active malignancy other than skin cancer.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)Chronic obstructive pulmonary disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2012-001172-12-ESovartis Pharma Services AG576
进行中（未招募）
1 期
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)Chronic obstructive pulmonary disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2012-001172-12-BEovartis Pharma Services AG576
进行中（未招募）
不适用
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)EUCTR2012-001172-12-BGovartis Pharma Services AG576
进行中（未招募）
1 期
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with COPDEUCTR2012-001172-12-FIovartis Pharma Services AG629
进行中（未招募）
不适用
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with COPDCOPDMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2012-001172-12-DKovartis Pharma Services AG576